Actos (pioglitazone) is an oral medication used with diet and exercise to lower blood sugar in adults with type 2 diabetes. It belongs to a class called thiazolidinediones (TZDs) and works by making muscle, fat, and liver cells more sensitive to insulin. Actos is not used for type 1 diabetes or diabetic ketoacidosis.
How Actos Works
Pioglitazone activates a nuclear receptor called peroxisome proliferator-activated receptor gamma (PPAR-gamma). Activating PPAR-gamma changes the expression of genes that control glucose uptake, fatty acid storage, and adipocyte differentiation. The end result is improved insulin sensitivity in peripheral tissues and reduced glucose production by the liver.
Unlike insulin secretagogues such as sulfonylureas, Actos does not force the pancreas to release more insulin. This mechanism makes it especially useful in people with clear insulin resistance — the same physiology that underlies most prediabetes. For context, see our overview of what prediabetes is and how insulin resistance drives it.
Who Is Prescribed Actos
The FDA has approved Actos for adults with type 2 diabetes as monotherapy or combined with metformin, a sulfonylurea, or insulin. In practice, clinicians often consider Actos for:
- Adults with marked insulin resistance (elevated triglycerides, low HDL, central obesity)
- Patients who cannot tolerate or have not reached A1C goal on metformin
- Those with nonalcoholic steatohepatitis (NASH), where pioglitazone has shown histologic improvement
- People who need a low-cost oral option (generic pioglitazone is inexpensive)
How Well Actos Lowers A1C
According to the FDA prescribing information and randomized trials, Actos lowers A1C by about 1.0 to 1.5 percentage points, similar to metformin and larger than DPP-4 inhibitors. It also lowers fasting glucose, improves triglycerides, and raises HDL cholesterol. The PROactive trial showed a reduction in the composite secondary endpoint of death, myocardial infarction, and stroke in people with established cardiovascular disease, though the primary endpoint was not met.
To understand how those A1C changes translate to your target, review the A1C levels guide.
Dosing and Administration
Actos is taken once daily with or without food. The starting dose depends on the clinical situation:
| Situation | Starting Dose | Maximum |
|---|---|---|
| Monotherapy, no heart failure risk | 15 or 30 mg once daily | 45 mg daily |
| Combination with other agents | 15 to 30 mg daily | 45 mg daily |
| With strong CYP2C8 inhibitor (gemfibrozil) | Maximum 15 mg daily | 15 mg daily |
| Mild to moderate heart failure (NYHA I-II) | 15 mg daily, cautiously | Lower individualized dose |
Do not split or crush Actos tablets unless your pharmacist confirms it is acceptable. Miss a dose? Take it when you remember unless it is almost time for the next dose. Never double up.
Common Side Effects
The side effects most often reported in Actos clinical trials were:
- Upper respiratory tract infection
- Headache
- Sinusitis
- Mild muscle pain (myalgia)
- Tooth problems
- Weight gain (2 to 6 pounds typically)
- Mild peripheral edema (swelling of ankles)
Boxed Warning and Serious Risks
Actos carries a boxed warning and several important risks. Every prescriber should review these before starting the drug.
Congestive Heart Failure
The FDA boxed warning states that thiazolidinediones, including pioglitazone, can cause or worsen congestive heart failure. Actos is contraindicated in patients with NYHA Class III or IV heart failure. In Class I or II, it should be started at the lowest dose with close monitoring for rapid weight gain, shortness of breath, or edema.
Bladder Cancer
Observational data from the Kaiser Permanente Northern California cohort and subsequent meta-analyses suggest a small increased risk of bladder cancer with long-term pioglitazone use (more than 1 to 2 years). The FDA label recommends against use in patients with active bladder cancer and caution in those with a history.
Bone Fractures
Long-term Actos use increases fracture risk, especially in postmenopausal women and in the upper arm, hand, and foot. This reflects pioglitazone’s effect on bone turnover. Assess fall and fracture risk before prescribing and consider bone density screening.
Macular Edema
Diabetic macular edema has been reported in patients taking Actos. Those with diabetic retinopathy should have a dilated eye exam before and during therapy, and any change in vision should be reported immediately.
Liver Injury
Post-marketing reports of severe liver injury exist, although the risk is much lower than with the related drug troglitazone (which was withdrawn). Baseline liver enzymes should be checked, and Actos should not be used if ALT is greater than 2.5 times the upper limit of normal.
Hypoglycemia
Used alone, Actos rarely causes hypoglycemia. Combining it with insulin or a sulfonylurea raises the risk and usually requires lowering the dose of the other drug.
Drug Interactions
Gemfibrozil, a CYP2C8 inhibitor, roughly triples pioglitazone levels. If coadministration is unavoidable, cap the Actos dose at 15 mg daily. Rifampin is a strong CYP2C8 inducer that lowers pioglitazone levels — a higher Actos dose may be needed. Actos can also reduce the effectiveness of oral contraceptives; reproductive-age patients should discuss alternative or additional contraception.
Who Should Avoid Actos
Pioglitazone is not a good fit for everyone. It is contraindicated or cautiously avoided in:
- Type 1 diabetes or diabetic ketoacidosis
- NYHA Class III or IV heart failure
- Active bladder cancer
- Symptomatic liver disease or ALT above 2.5 times upper limit of normal
- Pregnancy (limited safety data; insulin is preferred)
- Children under 18 (safety not established)
- High fracture risk in postmenopausal women
Monitoring on Actos
Routine follow-up captures both benefits and warning signs. Expect your care team to check:
- A1C every 3 months until stable, then every 6 months
- Weight and signs of fluid retention (ankle swelling, shortness of breath)
- Liver enzymes (ALT/AST) at baseline and periodically
- Eye exam annually for diabetic retinopathy
- Urinalysis if hematuria is reported
- Bone density in high-risk postmenopausal women
Actos vs. Other Oral Diabetes Medications
| Class | A1C Reduction | Weight Effect | Key Risks |
|---|---|---|---|
| Thiazolidinedione (Actos) | 1.0 to 1.5% | Gain | Heart failure, fractures, bladder cancer |
| Biguanide (Metformin) | 1.0 to 1.5% | Neutral to slight loss | GI upset, rare lactic acidosis |
| DPP-4 inhibitor (Januvia) | 0.5 to 0.8% | Neutral | Pancreatitis, joint pain |
| SGLT2 inhibitor (Jardiance) | 0.7 to 1.0% | Loss | Genital infections, DKA |
| GLP-1 agonist (Ozempic) | 1.0 to 1.8% | Loss | Nausea, rare pancreatitis |
Cost and Availability
Generic pioglitazone has been available since 2012 and is one of the least expensive oral diabetes drugs in the United States, often priced under $20 per month at major pharmacies with a discount card. Most insurance formularies cover it at the lowest copay tier.
Lifestyle Remains Central
Actos works through insulin sensitivity, but weight loss, regular aerobic and resistance training, and a Mediterranean-style or low-carbohydrate eating pattern amplify its effect. The National Diabetes Prevention Program showed that 5 to 7 percent weight loss plus 150 minutes of weekly activity reduced progression from prediabetes to type 2 diabetes by 58 percent — outperforming any single drug.
When to Contact Your Doctor
Call your prescriber for:
- Rapid weight gain (more than 5 pounds in a week)
- New shortness of breath or ankle swelling
- Blood in the urine or painful urination
- Sudden bone pain or a fall with injury
- Blurred or changing vision
- Yellowing of skin or eyes, dark urine, right upper abdominal pain
- Hypoglycemia symptoms if you also take insulin or a sulfonylurea
The Bottom Line
Actos is an inexpensive, once-daily oral drug that meaningfully lowers A1C by tackling insulin resistance — the root of most type 2 diabetes. It offers unique benefits in NASH and may reduce cardiovascular events in some patients, but it also carries real risks: fluid overload, fractures, and a small long-term bladder cancer signal. Weighed against modern alternatives, pioglitazone still has a place, especially when cost is a major factor. Discuss your personal risk profile with your clinician before starting, and commit to the lifestyle changes that no medication can replace.
